Search results
Results from the WOW.Com Content Network
Safety risks and accessibility of new Alzheimer’s drugs The modest clinical benefits conferred by anti-amyloid antibody treatments need to be weighed against the risks, costs, and accessibility ...
If you have a loved one with Alzheimer’s disease, you may have read about a newly approved drug. And you may have heard that the drug has caused some controversy. So, what’s really going on ...
This trial proves that Alzheimer’s disease can be treated.” NEW DATA: Topline data from the confirmatory Phase 3 CLARITY AD trial is now available for our investigational anti-amyloid-beta ...
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology.
Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.
Intepirdine is a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies. [ 4 ] [ 1 ] [ 5 ] GlaxoSmithKline had sold the rights to Axovant for only $5 million, a very small amount in the pharmaceutical industry, because four clinical trials had resulted in failure.
A new Alzheimer's drug is being hailed as a "turning point" in the fight against the disease, with researchers saying it marks the beginning of a "new era where Alzheimer's could become treatable".
In addition, a roundtable of Alzheimer's experts recommends patients get periodic brain scans to monitor for any side effects. Leqembi will carry a list price of $26,500 a year .